Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bio-STAMP: Dutasteride + Abiraterone in Prostate Cancer
NCT05705700Phase 2Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Feb 2023
- Primary completion
- Jan 2030
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of dutasteride in prostate cancer (PCa) (3 arms), sponsored by Masonic Cancer Center. Primary endpoint: Radiographic Progression Free Survival at 24 weeks. Planned start Feb 2023; status: withdrawn.
02
Drugs
dutasteride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05705700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05705700.